We have observed
1 EP application
has served for within the last five+ years.
(We consider all applications which have an EP A1 or A2 publication dated after March 15, 2013).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
Method of determination of cancer cell drug sensitivity towards Aurora kinase inhibitors and overcoming their resistance